ClinicalTrials.gg
Active, not recruitingNCT05469789Updated Nov 20, 2025

A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)

An observational study in Hereditary Angioedema (HAE), sponsored by Takeda. Active, not recruiting at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Takeda · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
50
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 58 studies in Angioedemas, Hereditary by Takeda — 3 open to participants now, 4 under way, none of them phase 3. Angioedemas, Hereditary · Takeda.

Planned enrollment
14th of 21
50 · median 83
Started
2023
with 1 other
Observational
21 of 58
2 open now
Registered
48th of 58
by date

Among the 58 studies in Angioedemas, Hereditary by Takeda, this one is the 14th largest by planned enrollment of the 21 observational ones that give a count, is one of 2 that started in 2023, is one of 21 observational ones, and was the 48th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

3 of the 58 studies in Angioedemas, Hereditary by Takeda are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Angioedemas, Hereditary by Takeda, or all of them as a file.
02

Study summary

The main aim of this study is to compare the HAE attacks (both total and those requiring on-demand treatment) in the 12 months before and up to 24 months after initiation of treatment with lanadelumab.

This study is conducted in the United Kingdom where participants were treated or about to be treated with landelumab according to their routine practice at hospitals. Data will be directly collected from participants via study diaries, questionnaires, their medical records, and study doctors treating them. Participants will be contacted every 3 months during study participation (via phone).

03

Conditions studied

  • Hereditary Angioedema (HAE)

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The population of this survey is all participants with HAE type I or II treated with lanadelumab in hospitals within the UK.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of HAE type I or II (confirmed through laboratory testing)
  • Documented initiation of treatment with lanadelumab or due to be initiated within next 4 weeks
  • Greater than or equal to (≥)12 years of age at initiation of treatment with lanadelumab
  • ≥12 months of continuous medical record data before initiation of treatment with lanadelumab

Exclusion criteria

Exclusion:

  • Exposure to lanadelumab administered as an investigation product in a clinical trial setting at any point in time
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Prevalent Cohort A

    Prevalent Cohort A will comprise eligible participants with HAE type I or II who have initiated treatment with lanadelumab at any point in time (i.e., all prevalent cases of exposure to lanadelumab). The total follow-up encompasses a 12-month pre-treatment period, and an up-to 24-month post-treatment period.

    Other: No Intervention

  • Prevalent Cohort B

    Prevalent Cohort B will comprise eligible participants with HAE type I or II who have been treated with lanadelumab for \<12 months (i.e., the subset of participants from Prevalent Cohort A who initiated treatment with lanadelumab within \<12 months). The total follow-up encompasses a 12-month pre-treatment and an up to 24-month post-treatment period, as well as a prospective data collection period of participant-specific duration.

    Other: No Intervention

  • Incident Cohort A

    Incident Cohort A will comprise eligible participants with HAE type I or II initiating treatment with lanadelumab at any time within the prospective data collection time period. The total follow-up encompasses a 12-month pre-treatment and an up-to 24-month post-treatment period, as well as a prospective data collection period of participant-specific duration.

    Other: No Intervention

Interventions

  • OtherNo Intervention

    As it is an observational study, no intervention is administered in this study.

06

What researchers measure

Primary outcomes

  1. Number of Hereditary Angioedema (HAE) Attacks

    Number of HAE attacks (both total \[including untreated\] and those requiring on-demand treatment) will be estimated across the pre- and post-treatment periods (that is, 12 months before and up to 24 months after initiation of treatment with lanadelumab).

    Time frame: Up to approximately 3 years

Secondary outcomes

  1. Number of Participants Categorized by Their Demographic Characteristics

    Demographic characteristics will include age, sex, and ethnic group at index.

    Time frame: At index (lanadelumab treatment initiation day)

  2. Number of Participants Categorized by Their Clinical Characteristics

    Clinical characteristics will include categories of participant-reported age at onset of symptoms, age at diagnosis of HAE, duration of time from onset to diagnosis (i.e., the diagnostic delay), body mass index (BMI) (at index); comorbidities (pre and post index), history of laryngeal attacks (pre index), type of HAE (type I and II), and triggers for HAE symptoms onset (at index and post index). Index is defined as the lanadelumab treatment initiation day.

    Time frame: Up to approximately 3 years

  3. Number of Participants Categorized by Their Treatment Patterns

    Treatment patterns will include categories of the summary of participant-reported duration of lanadelumab treatment, treatment dose given to participants, and participant with switching patterns with lanadelumab on occurence of HAE attacks.

    Time frame: At and after index (lanadelumab treatment initiation day plus approximately 2 years)

  4. Number of Participants Categorized by Their Patterns of Prophylactic Treatment

    Patterns of prophylactic treatment will include categories of the summary of participant-reported use of brand and drug name, duration of treatment, dose of the treatment within same class of prophylactic treatments.

    Time frame: Up to approximately 3 years

  5. Compare the Number of Participants Categorized by Their Clinical Features of HAE Attacks Before and After Initiation of Lanadelumab

    To compare the number clinical features of HAE attacks before and after initiation of lanadelumab. Clinical features of HAE attacks will include categories of summary of participant-reported time of attack, duration of attack, location (e.g., trunk, extremities, and larynx) of HAE attack, the severity (Grade 1 \[Mild\], Grade 2 \[Moderate\], and Grade 3 \[Severe\]) of HAE attack, and hospitalization due to the HAE attack.

    Time frame: Up to approximately 3 years

  6. Number of Self-Reported HAE Attacks

    Time frame: Up to approximately 3 years

  7. Number of Participants Categorized by Their Clinical Features of Self-Reported HAE Attacks

    Clinical features of self-reported HAE attacks will include categories of summary of participant-reported time of attack, duration of attack, location (e.g., trunk, extremities, and larynx) of HAE attack, the severity (Grade 1 \[Mild\], Grade 2 \[Moderate\], and Grade 3 \[Severe\]) of HAE attack, symptoms of HAE attack (e.g., tiredness, abdominal pain, and abdominal swelling), and identified or suspected trigger(s) for the attack (e.g., contact with chemicals, drugs, or foods).

    Time frame: Up to approximately 3 years

  8. European Quality of Life 5 Dimensions 3-levels (EQ-5D-3L) Questionnaire Total Score

    The EQ-5D-5L questionnaire will be used to record impact of HAE on participant's quality-of-life (QoL). The EQ-5D-5L is a descriptive system of Health-Related Quality-of-Life (HRQoL) states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each of which can take 1 of 5 responses. The responses record 5 levels of severity \[no problems, slight problems, moderate problems, severe problems, and extreme problems\] within a particular dimension. The scores will be the sum of scores from each dimension and can range from 5 (no problems) to 25 (extreme problems). Higher score indicated a worsening health condition.

    Time frame: Up to approximately 2 years

  9. EQ-5D-3L Visual Analogue Scale (VAS) Score

    The EQ-5D-3L VAS records the participant's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS is used as a quantitative measure of health outcome that reflect the participant's own judgement score, with a score of 0 as the worst and 100 as the best possible health.

    Time frame: Up to approximately 2 years

  10. Angioedema Quality of Life (AE-QoL) Total Scores

    AE-QoL is a self-administered instrument designed to measure HRQoL in adult participants with recurrent angioedema. The AE-QoL consists of 17 disease-specific quality-of-life items, to produce a total AE-QoL score and 4 domain scores (functioning, fatigue/mood, fears/shame, and food, Each of the 17 items has a five-point response scale ranging from 1 (Never) to 5 (Very Often).

    Time frame: Up to approximately 2 years

  11. Angioedema Quality of Life (AE-QoL) Domain Scores

    AE-QoL is a self-administered instrument designed to measure HRQoL in adult participants with recurrent angioedema. The AE-QoL consists of 17 disease-specific quality-of-life items, to produce a total AE-QoL score and 4 domain scores (functioning, fatigue/mood, fears/shame, and food, Each of the 17 items has a five-point response scale ranging from 1 (Never) to 5 (Very Often).

    Time frame: Up to approximately 2 years

  12. Number of Participants With HAE-related Health Care Resource Utilization (HCRU)

    Healthcare resources used during medical encounters include in and out-patient visits to physicians, hospital admissions, in and out-patient emergency care, and in and out-patient clinical examinations and tests.

    Time frame: Up to approximately 3 years

  13. Angioedema Control Test (AECT) Total Score

    The AECT is used to assess participants with recurrent angioedema. The test uses a questionnaire with 4 items, each of which has 5 options and is used to measure the participant's current disease control. HAE control score will be recorded with 5 levels of answers \[1=very often, 2=often, 3=sometimes, 4=seldom, 5=not at all\] to the following questions: 1) In the last 3 months, how often have you had angioedema? 2) In the last 3 months, how much has your QoL been affected by angioedema? 3) In the last 3 months, how much has the unpredictability of your angioedema bothered you? 4) In the last 3 months, how well has your angioedema been controlled by your therapy?

    Time frame: Up to approximately 2 years

  14. Angioedema Control Test (AECT) Domain Score

    The AECT is used to assess participants with recurrent angioedema. The test uses a questionnaire with 4 items, each of which has 5 options and is used to measure the participant's current disease control. HAE control score will be recorded with 5 levels of answers \[1=very often, 2=often, 3=sometimes, 4=seldom, 5=not at all\] to the following questions: 1) In the last 3 months, how often have you had angioedema? 2) In the last 3 months, how much has your QoL been affected by angioedema? 3) In the last 3 months, how much has the unpredictability of your angioedema bothered you? 4) In the last 3 months, how well has your angioedema been controlled by your therapy?

    Time frame: Up to approximately 2 years

  15. Treatment Satisfaction Questionnaire for Medication (TSQM) Total Score

    The TSQM comprises 14 items across four domains focusing on effectiveness (three items), side effects (five items), convenience (three items), and global satisfaction (three items) of the medication over the previous 2-3 weeks, or since the patient's last use. With the exception of item 4 (presence of side effects; yes or no), all items have five or seven responses, scored from one (least satisfied) to five or seven (most satisfied). The 7-item scales had a non-neutral midpoint, such that there were more positive response options than negative response options, to allow for precise information to be obtained at the upper end of the score distribution. Item scores are summed to give four domain scores, which are in turn transformed to a scale of 0-100.

    Time frame: Up to approximately 2 years

  16. Treatment Satisfaction Questionnaire for Medication (TSQM) Domain Score

    The TSQM comprises 14 items across four domains focusing on effectiveness (three items), side effects (five items), convenience (three items), and global satisfaction (three items) of the medication over the previous 2-3 weeks, or since the patient's last use. With the exception of item 4 (presence of side effects; yes or no), all items have five or seven responses, scored from one (least satisfied) to five or seven (most satisfied). The 7-item scales had a non-neutral midpoint, such that there were more positive response options than negative response options, to allow for precise information to be obtained at the upper end of the score distribution. Item scores are summed to give four domain scores, which are in turn transformed to a scale of 0-100.

    Time frame: Up to approximately 2 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Dec 2026, 42 months after the start.

Of 27 observational studies under Angioedemas, Hereditary, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 52. This study's planned 42 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2022
First posted
Jul 22, 2022
StartActual
Jun 29, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05469789
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jul 22, 2022
Start date
Jun 29, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 20, 2025

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion